Clinical Trial Update: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers [Phase 1]

View source ↗

Summary

This document outlines an ongoing Phase 1 trial evaluating NKX019, an allogeneic CAR NK cell therapy, in adults with B-cell cancers including various non-Hodgki…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Indolent Non-hodgkin Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• NKX019

Snippet

Sponsor: Nkarta, Inc. | Conditions: Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING